US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Trans Care In Court: Gov't Probes, Forum Concerns And More No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at developments over the past week in legal challenges to probes by the Justice Department and Feder... (more story)

A Battle Bigger Than Abortion Pills On Deck At High Court No Photo Available

Dan McKay

The outcome of the latest abortion clash at the high court could reach well beyond mifepristone access and make other federal policy c... (more story)

This Week's Healthcare Earnings: Novo, Hims And More No Photo Available

Yeji Jesse Lee

The healthcare industry wrapped up its first-quarter earnings readouts this week, closing off the season with major names like Novo Nordisk and CVS.